WAVE Life Sciences (NASDAQ:WVE) Stock Bumped Up to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of WAVE Life Sciences (NASDAQ:WVE) from a strong sell rating to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

A number of other research analysts also recently commented on WVE. Mizuho decreased their price objective on shares of WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. JPMorgan Chase & Co. started coverage on shares of WAVE Life Sciences in a report on Wednesday, September 23rd. They issued a “neutral” rating on the stock. William Blair started coverage on shares of WAVE Life Sciences in a research note on Friday, October 16th. They issued an “outperform” rating for the company. Zacks Research cut WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, UBS Group began coverage on WAVE Life Sciences in a research report on Thursday, October 15th. They set a “buy” rating and a $11.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $20.89.

WAVE Life Sciences Price Performance

Shares of NASDAQ WVE opened at $3.59 on Friday. The stock has a market capitalization of $708.06 million, a price-to-earnings ratio of -3.36 and a beta of -1.43. The business has a 50-day moving average of $4.07 and a 200-day moving average of $7.49. WAVE Life Sciences has a fifty-two week low of $3.04 and a fifty-two week high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last released its earnings results on Tuesday, October 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. WAVE Life Sciences had a negative return on equity of 44.66% and a negative net margin of 296.86%. The business had revenue of $13.16 million for the quarter, compared to the consensus estimate of $4.51 million. On average, sell-side analysts expect that WAVE Life Sciences will post -1.09 EPS for the current year.

Insider Activity at WAVE Life Sciences

In other news, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total transaction of $67,183.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Heidi Wagner sold 7,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total value of $42,070.00. Following the transaction, the director owned 44,930 shares in the company, valued at approximately $270,029.30. This trade represents a 13.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 23,564 shares of company stock worth $132,476 in the last ninety days. 24.34% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Readystate Asset Management LP acquired a new position in WAVE Life Sciences in the second quarter valued at about $27,465,000. Squarepoint Ops LLC grew its stake in WAVE Life Sciences by 68.0% during the second quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock worth $14,766,000 after buying an additional 1,029,052 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in WAVE Life Sciences by 42.6% during the first quarter. Pictet Asset Management Holding SA now owns 1,149,127 shares of the company’s stock worth $8,202,000 after buying an additional 343,226 shares in the last quarter. Renaissance Technologies LLC grew its stake in WAVE Life Sciences by 152.6% during the first quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock worth $4,330,000 after buying an additional 360,800 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in WAVE Life Sciences by 12.4% in the 1st quarter. Bank of New York Mellon Corp now owns 361,204 shares of the company’s stock valued at $2,619,000 after buying an additional 39,759 shares during the period. Institutional investors own 89.73% of the company’s stock.

WAVE Life Sciences News Roundup

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE reported third-quarter revenue of $13.16 million, well above the $4.51 million analyst consensus, while its $0.30 per-share loss was narrower than the expected $0.33 loss. The results helped ease concerns about the company’s financial performance and contributed to a recent share-price rally. Wave Life Sciences stock rallies as Q3 results ease loss fears
• Positive Sentiment: HC Wainwright initiated coverage with a “Strong-Buy” rating, offering a favorable view of WAVE’s long-term prospects. The firm forecasts a $1.09-per-share loss for fiscal 2026 and fiscal 2027, improving to losses of $0.79 in fiscal 2028, $0.68 in fiscal 2029 and $0.47 in fiscal 2030. HC Wainwright stock recommendations
• Neutral Sentiment: HC Wainwright’s quarterly forecasts call for continued losses, ranging from $0.26 to $0.31 per share through the near-term reporting periods. The estimates imply that investors will likely focus on clinical progress, revenue growth and the company’s ability to reduce cash burn rather than near-term profitability.
• Negative Sentiment: Despite beating estimates, WAVE remains deeply unprofitable, with a negative net margin and analyst expectations for another full-year loss. Its shares also remain well below the 52-week high, reflecting continuing execution and biotechnology-sector risks.

About WAVE Life Sciences

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.